Merck & Company Inc (MRK)vsPureTech Health PLC (PRTC)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
PRTC
PureTech Health PLC
$17.40
-4.08%
HEALTHCARE · Cap: $441.56M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1017127% more annual revenue ($65.01B vs $6.39M). PRTC leads profitability with a 793.0% profit margin vs 28.1%. PRTC trades at a lower P/E of 10.7x. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
PRTC
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Intrinsic value data unavailable for PRTC.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Keeps 793 of every $100 in revenue as profit
Revenue surging 543.0% year-over-year
Earnings expanding 61.5% YoY
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Smaller company, higher risk/reward
Negative free cash flow — burning cash
Operating margin of -2590.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : PRTC
The strongest argument for PRTC centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 793.0% and operating margin at -2590.0%. Revenue growth of 543.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : PRTC
The primary concerns for PRTC are Market Cap, Free Cash Flow, Operating Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while PRTC is a growth play — different risk/reward profiles.
PRTC carries more volatility with a beta of 0.71 — expect wider price swings.
PRTC is growing revenue faster at 543.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 51/100), backed by strong 28.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →PureTech Health PLC
HEALTHCARE · BIOTECHNOLOGY · USA
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops and markets drugs for inflammatory, fibrotic and immune, intractable, lymphatic and gastrointestinal, neurological and neuropsychological cancers and other diseases in the United States. The company is headquartered in Boston, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?